Cartesian Growth Corp. III Class A ( (CGCT)) just unveiled an announcement. On December 17, 2025, Cartesian Growth Corporation III and Factorial Inc. signed a definitive business combination agreement ...

Factorial’s high-power, lightweight, solid-state batteries have demonstrated real-world performance, including over 1,200 km (745 miles) of driving range in vehicle testing and are being advanced ...

Cyber attacks are a constant threat for organisations, with most facing the question of when, not if, they will be targeted. Just as businesses adopt new technology and processes to harden their ...

Cyber crime is now the number one global business risk. Cyber attacks are a constant threat for organisations, with most facing the question of when, not if, they will be targeted. Just as businesses ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...

Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...

FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

NEW YORK--(BUSINESS WIRE)--Cartesian Growth Corporation III (the “Company”) announced today the pricing of its initial public offering of 24,000,000 units, upsized from 20,000,000 units, at a price of ...

After military service a career as war correspondent was on the cards. But then an exclusive bursar programme in automotive journalism came 'a-knockin' - and so a 26-year journey spanning newspapers, ...